main content start

Video Shorts

Most Popular

Most Popular

Popular in No name
  • OncoSpecials2m 41s

    Low Dose Dasatinib Ready For Clinical Practice

    Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.
    low dose dasatinib dasatinib 50mg
  • Multiple Myeloma4m 12s

    Key Practice Points -Myeloma Related Renal Impairment

    In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.
    myeloma renal impairment key practice points
  • Oncology3m 36s

    Tissue Agnostic Treatment options in Solid Tumors

    Tissue-agnostic treatment based on shared genetic aberrations have provided a new direction in cancer treatment. Emerging clinical evidence indicates that many molecular aberrations can be common across tumor types with different site of origin.
    personalized medicine precision medicine tissue agnostic treatment
  • Prostate Cancer2m 21s

    Role of Geriatric Assessment in prostate Cancer

    Average at diagnosis of prostate cancer is ~65 years & patients usually have multiple co- morbidities and may be on treatment with multiple prescribed medications.
    geriatric assessment prostate cancer
  • Multiple Myeloma3m 11s

    Tips on using Pomalidomide Based Regimens in Multiple Myeloma

    For relapsed and refractory multiple myeloma, use of pomalidomide often in combination with dexamethasone or other agents is recommended in patients who have failed at least two prior treatments, including lenalidomide and a proteasome inhibitor.
    clinical practice tips improved patient outcomes rrmm management pomalidomide
  • Multiple Myeloma3m 16s

    Need of Geriatric assessment in Multiple Myeloma

    Majority of Myeloma patients are > 65 years of age at diagnosis & that makes Geriatric Assessment a critical for these patients. Historically we have focused on Cytogenetic & Biochemical evaluation but not so much on geriatric assessment.
    geriatric assessment multiple myeloma quality of life
  • Myelodysplastic Syndromes2m 31s

    Duration of treatment does it improve outcomes Hypomethylating agents in MD

    Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.
    duration of treatment hypomethylating agents mds
  • Prostate Cancer3m 54s

    ASCO Genitourinary Cancers Symposium– Your Top Takeways for Prostate Cancer

    ASCO GU 2022 had 4 important clinical trials in prostate cancer discussed in plenary session as follows.
    abiraterone asco gu 2022 conference update olaparib prostate cancer
  • Myelodysplastic Syndromes2m 25s

    Factors that influence treatment adherence and outcomes in MDS

    Anticipate & manage adverse events to optimize treatment outcomes: Patients treated with hypomethylating agents are at increased risk of cytopenias & might need support with transfusions.
    adverse events hypomethylating agents mds treatment compliance
  • Oncology2m 8s

    Cardio Oncology & and its integration in Cancer Treatment planning

    Cardiac care is not fully integrated in cancer care plans in most canters across the world. This is an important next step in evolution of cancer care.
    cardiac care cardio oncology safety
  • Latest

    Latest

    Category Short Cards Listing

    All Videos

    All Videos

    Brightcove Tab Listing
    Sort by
    4m 34s
    Myelodysplastic...
    4m 0s
    Myelodysplastic...
    3m 11s
    Multiple Myeloma
    4m 12s
    Multiple Myeloma
    2m 41s
    OncoSpecials
    4m 19s
    Prostate Cancer
    Hi, can I help?
    Chat SupportX
    Support Team
    Hello, how can I help you today?
    Please select one of the below options.

    Find Information

    Unable to Login or Register

    Want to share feedback